Drug Trial Radar · NCT07224360
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
63
Planned (sponsor's estimate)
Start
Feb 2, 2026
Primary completion
Aug 15, 2028
Study completion Aug 15, 2028
Sponsor
- Lead sponsor
- CSL BehringIndustry
- Sponsor type
- Industry
- First posted
- Nov 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered subcutaneously (SC) at the maximum tolerated dose (MTD) in adult participants with SCD. The primary aim of the study is to assess the safety of anumigilimab in participants with SCD. Participants will be treated for 64 weeks: for 12 weeks in the dose escalation period, where the dose will be escalated to each participant's individual MTD; and for 52 weeks at the MTD in the maintenance period.
Conditions
- Sickle Cell Disease
Interventions
AnumigilimabBiological
Participants will receive anumigilimab, escalated to a maximum dose guided by absolute neutrophil count (ANC) and safety concerns.
PlaceboDrug
Volume matched saline will be administered SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Treatment Emergent Adverse Events (TEAEs), Overall and by severity, seriousness and relationship to Investigational Product (IP)Time frame: From baseline up to Week 75
- Percentage of participants with TEAEs Overall and by severity, seriousness and relationship to IPTime frame: From baseline up to Week 75
- Number of participants with Adverse Events of Special Interest (AESI)Time frame: From baseline up to Week 75
- Percentage of participants with AESITime frame: From baseline up to Week 75
- Number of participants with clinically relevant changes from baseline in laboratory assessments and vital signsTime frame: From baseline up to Week 75
- Percentage of participants with clinically relevant changes from baseline in laboratory assessments and vital signsTime frame: From baseline up to Week 75
Locations
38 sites in 7 countries. Site status is shown where the registry gives one.
UAMS Medical Center
Little Rock, Arkansas · Recruiting
University of California Irvine
Orange, California · Recruiting
The Foundation for Sickle Cell Disease
Hollywood, Florida · Recruiting
Arthur M. Blank Hospital- Children's Healthcare of Atlanta
Atlanta, Georgia · Recruiting
Center for Cancer and Blood Disorders
Bethesda, Maryland · Recruiting
Boston Medical Center
Boston, Massachusetts · Recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
Southern Specialty Research
Flowood, Mississippi · Recruiting
NYC Health + Hospitals/Queens
Jamaica, New York · Recruiting
Columbia University Medical Center
New York, New York · Recruiting
Jacobi Medical Center
The Bronx, New York · Recruiting
Ohio State University
Columbus, Ohio · Recruiting
UT Physicians Comprehensive Adult Sickle Cell Center
Houston, Texas · Recruiting
Virginia Commonwealth University
Richmond, Virginia · Recruiting
CHU Saint-Pierre
Brussels, Belgium · Recruiting
UZ Antwerpen
Edegem, Antwerp, Belgium · Recruiting
CHU de Nantes, Hotel-Dieu
Nantes, France · Recruiting
CHU de Rouen-Hôpital Charles-Nicolle
Rouen, France · Recruiting
Institut Universitaire du Cancer de Toulouse
Toulou, France · Recruiting
AP-HM Hôpital de La Timone
Marseille, Bouches-du-Rhône, France · Recruiting
IRCCS Istituto Giannina Gaslini
Genoa, Italy · Recruiting
Fondazione IRCCS San Gerardo dei Tintori
Monza, Italy · Recruiting
AORN Antonio Cardarelli
Naples, Italy · Recruiting
IRCCS Bambino Gesù Children's Hospital
Rome, Italy · Recruiting
AOUI Verona and University of Verona
Verona, Italy · Recruiting
Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant' Anna
Cona, Ferrara, Italy · Recruiting
Amsterdam UMC - VUmc
Amsterdam, North Holland, Netherlands · Recruiting
Acibadem Adana Hastanesi
Adana, Turkey (Türkiye) · Recruiting
Hacettepe University Medical Faculty
Ankara, Turkey (Türkiye) · Recruiting
VM Medical Park Mersin Hospital
Mezitli, Mersin, Turkey (Türkiye) · Recruiting
Mersin University Medical Faculty
Yenişehir, Mersin, Turkey (Türkiye) · Recruiting
Royal Liverpool University Hospital
Liverpool, United Kingdom · Recruiting
The Royal London Hospital
London, United Kingdom · Recruiting
Central Middlesex Hospital
London, United Kingdom · Recruiting
Guy's Hospital
London, United Kingdom · Recruiting
St George's University Hopsitals NHS Foundation Trust
London, United Kingdom · Recruiting
Hammersmith Hospital Imperial College Healthcare NHS Trust
London, United Kingdom · Recruiting
Manchester Royal Infirmary
Manchester, England, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.